SCHEMBL13459817

SCHEMBL13459817

O=C(Nc1ccc(-c2cccc3cnccc23)cc1)Nc1ccc(O)c(O)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPV1 Q8NER1 6/20 0.53
▸ IMPDH2 P12268 5/20 0.49
▸ CYP3A4 P08684 1/20 0.46
▸ CYP3A5 P20815 1/20 0.46
▸ RIPK1 Q13546 2/20 0.45
▸ KDR P35968 3/20 0.45
▸ CSF1R P07333 2/20 0.45
▸ FLT1 P17948 2/20 0.45
▸ RPS6KB1 P23443 2/20 0.45
▸ FLT3 P36888 2/20 0.45
▸ AURKA O14965 1/20 0.45
▸ ROCK2 O75116 1/20 0.45
▸ ERBB2 P04626 1/20 0.45
▸ TYK2 P29597 1/20 0.45
▸ AKT1 P31749 1/20 0.45
▸ FLT4 P35916 1/20 0.45
▸ RPS6KA3 P51812 1/20 0.45
▸ STK3 Q13188 1/20 0.45
▸ ROCK1 Q13464 1/20 0.45
▸ ERBB4 Q15303 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13632604 0.82 KDR (0.59) TRPV1KDR
SCHEMBL13459838 0.82 MEN1 (0.55) TRPV1IMPDH2CYP3A4KDRCSF1R
SCHEMBL13459571 0.81 IMPDH2 (0.51) TRPV1IMPDH2CYP3A4CYP3A5KDR
SCHEMBL13459592 0.80 RIPK1 (0.69) TRPV1RIPK1KDRCSF1RFLT1
SCHEMBL13459594 0.80 HTR2B (0.53) TRPV1IMPDH2CYP3A4CYP3A5KDR
SCHEMBL13459539 0.79 EGFR (0.60) TRPV1KDRCSF1RFLT1RPS6KB1
SCHEMBL13459834 0.78 CYP3A4 (0.58) TRPV1CYP3A4CYP3A5KDRROCK2
SCHEMBL4516431 0.76 RIPK1 (0.70) TRPV1RIPK1KDRCSF1RFLT1
SCHEMBL4527096 0.75 NPC1 (0.53) TRPV1IMPDH2KDR
SCHEMBL13632602 0.75 RIPK1 (0.61) TRPV1RIPK1KDRCSF1RFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010032986-A2 NOVEL 5-(4-AMINOPHENYL)-ISOQUINOLINE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PRODUCTION METHOD FOR SAME, AND COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PROPHYLAXIS AND TREATMENT OF MEDICAL CONDITION INDUCED BY RAF KINASE HYPERACTIVITY 주식회사 이큐스팜 (KR) 2010-03-25 — — WO disclosed
Send feedback